{"id":"W4415496300","doi":"10.1136/bmjno-2025-anzan.135","title":"3591 Tolebrutinib versus placebo in non-relapsing secondary progressive multiple sclerosis: efficacy and safety results from the phase 3 HERCULES trial","year":2025,"lang":"","type":"article","venue":"","topic":"Multiple Sclerosis Research Studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Placebo; Clinical trial; Phase (matter); Phases of clinical research","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00122928,0.001238778,0.002351267,0.0003326455,0.0003641152,0.0009236768,0.0005919012,0.001177891,0.006023556],"category_scores_gemma":[0.001191603,0.0002847948,0.001658236,0.0003323855,0.0006610699,0.0009165669,0.00029573,0.002737536,0.001190745],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006066927,"about_ca_system_score_gemma":0.0005420297,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0009832339,"about_ca_topic_score_gemma":0.002264212,"domain_scores_codex":[0.9994773,0.0002816533,0.00002429624,0.00007596228,0.00004318429,0.00009769548],"domain_scores_gemma":[0.9994961,0.0001700005,0.0001201703,0.0000367327,0.00003330187,0.0001436252],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9267808,0.003248758,0.0007490715,0.00102859,0.002119671,0.0000909533,0.00006186726,0.0006018943,0.004405788,0.0002288612,0.003063975,0.05761979],"study_design_scores_gemma":[0.9308396,0.05834929,0.006262701,0.0001187312,0.001081554,0.0001099571,0.00005176402,0.0005768898,0.0005081607,0.0004067523,0.001667083,0.00002749927],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9671632,0.02175728,0.0004920234,0.001419977,0.0004937292,0.0006418991,0.002072215,0.000270723,0.005688831],"genre_scores_gemma":[0.9862769,0.005463815,0.0006423263,0.001615859,0.000409614,0.0005077462,0.001614666,0.00003307263,0.003436123],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.006023556,"threshold_uncertainty_score":0.02015078,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.08260280902536478,"score_gpt":0.3627374319534252,"score_spread":0.2801346229280605,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}